This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Dwyer, P. J. Articles by Comis, R. L. Search for Related Content PubMed PubMed Citation Articles by O'Dwyer, P. J. Articles by Comis, R. L.

Phase I/Pharmacokinetic Reevaluation of ThioTEPA¹

Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [P. J. O'D., F. L., P. F. E., R. P., S. L., R. L. C.] Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892 [L. T., D. C., D. P.]; and Lederle Laboratories, Pearl River, New York 10965 [J. D., R. J. D.]

Because the initial evaluation of N,N',N''-triethylenethiophosphoramide (thioTEPA) preceded the standardized approach to the Phase I trials, uncertainty surrounds the recommended dose. Since it has recently been demonstrated that an almost 100-fold increase in dose can be administered in bone marrow transplant regimens, we conducted a Phase I reevaluation of thioTEPA. ThioTEPA was administered i.v. in 50 ml 5% dextrose in water over 10 min. Twenty-seven patients were entered at doses ranging from 30 to 75 mg/m². The major toxic effect was myelosuppression; thrombocytopenia grade 3 occurred in four of seven patients, and leukopenia grade 3 in two of seven patients at 75 mg/m². Among eight patients at 65 mg/m² only two had grade 3 myelosuppression making this the recommended new phase II dose for the majority of patients. Moderate (grade 2) easily controlled nausea and vomiting was the only other major side effect. There was no alopecia or mucosal or neurological toxicity. Three partial remissions were observed among nine previously treated ovarian cancer patients. Plasma concentrations of thioTEPA and its major active metabolite triethylenephosphoramide (TEPA) were measured by gas chromatography. The half-life of thioTEPA ranged from 51.6 to 211.8 min, and its pharmacokinetics was dose dependent; total body thioTEPA clearance decreased with increasing dose. The half-life of TEPA was considerably longer than that of the parent compound (3.0 to 21.1 h); as a result, the area under the plasma concentration-time curve (AUC) of TEPA was severalfold greater than that of the parent compound. The ratio of TEPA AUC to thioTEPA AUC decreased with increasing dose, suggesting that formation of TEPA is a saturable step in elimination. The AUC and total body clearance of thioTEPA, but not of TEPA, were closely correlated with neutrophil but not platelet toxicity.

¹ Supported in part by a grant from Lederle Laboratories and by National Cancer Institute Grant CA06927.

² To whom requests for reprints should be addressed, at Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111.

Received 4/11/90. Accepted 4/ 9/91.

This article has been cited by other articles:

				P. Stiff, B. Chen, W. Franklin, D. Oldenberg, E. Hsi, R. Bayer, E. Shpall, J. Douville, R. Mandalam, D. Malhotra, et al. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer Blood, March 15, 2000; 95(6): 2169 - 2174. [Abstract] [Full Text] [PDF]

				M. Zecca, A. Pession, C. Messina, F. Bonetti, C. Favre, A. Prete, S. Cesaro, F. Porta, I. Mazzarino, G. Giorgiani, et al. Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regimen for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings J. Clin. Oncol., June 1, 1999; 17(6): 1838 - 1838. [Abstract] [Full Text] [PDF]